This document is meant purely as documentation tool and the institutions do not assume any liability for its contents
"B COMMISSION DECISION
of 14 January 2000
detailing the distribution between antigen banks of antigen reserves established within the framework of
the Community action concerning reserves of foot-and-mouth disease vaccines and amending Commission
Decisions 93/590/EC and 97/348/EC
(notified under document number C(2000) 1)
(Text with EEA relevance)
(2000/112/EC)
(OJ L 33, 8.2.2000, p. 21)
Amended by:
Official Journal
No page date
"M1 Commission Decision 2000/707/EC of 6 November 2000 L 289 38 16.11.2000
"M2 Commission Decision 2001/181/EC of 22 February 2001 L 66 39 8.3.20012000D0112 — EN — 08.03.2001 — 002.001 — 1
COMMISSION DECISION
of 14 January 2000
detailing the distribution between antigen banks of antigen reserves
established within the framework of the Community action concerning
reserves of foot-and-mouth disease vaccines and amending Commission
Decisions 93/590/EC and 97/348/EC
(notified under document number C(2000) 1)
(Text with EEA relevance)
(2000/112/EC)
THE COMMISSION OF THE EUROPEAN COMMUNITIES,
Having regard to the Treaty establishing the European Community,Having regard to Council Decision 91/666/EEC of 11 December 1991
establishing Community reserves of foot-and-mouth disease vaccines (
1), as
last amended by Council Decision 1999/762/EC (2), and in particular Articles
7 thereof,
Whereas:(1) in accordance with Article 7 of Council Decision 91/666/EEC the
Commission shall adopt detailed arrangements in particular with
regard to the distribution of antigen reserves between antigen banks;
(2) Article 3 of Commission Decision 93/590/EC of 5 November 1993, for
the purchase of foot-and-mouth disease antigens within the framework
of the Community action concerning reserves of foot-and-mouthdisease vaccines (
3) as last amended by Decision 95/471/EC (4), makes
provisions for the antigen to be stored at three specified locations;
(3) Commission Decision 97/348/EC of 23 May 1997 for the purchase by
the Community of foot-and-mouth disease antigens and for the
formulation, production, bottling and distribution of vaccines againstfoot-and-mouth disease (
5), details the distribution of newly purchased
antigen to designated antigen banks;
(4) by Decision 2000/111/EC (6) the Commission designated Merial SAS,
Pirbright, United Kingdom as a third antigen bank and made
provisions for the transfer of antigen from a bank no longer
designated;
(5) as regards the quantities and types of antigen stored at designated
antigen banks account must be taken of the new situation and for thesake of clarity these quantities and types of antigen should be listed for
each designated antigen bank according to the new situation;
(6) the provisions of Article 3 of Decision 93/590/EC and of Article 5 of
Decision 97/348/EC are no longer adapted to the new situation and
should be repealed;
(7) the measures provided for in this Decision are in accordance with the
opinion of the Standing Veterinry Committee,
HAS ADOPTED THIS DECISION:
Article 1
The quantities and types of antigen stored within the framework of
Community reserves of foot-and-mouth disease antigen shall be distributedbetween designated antigen banks in accordance with the provisions in the
Annex.!B
(1) OJ L 368, 31.12.1991, p. 21.
(2) OJ L 301, 24.11.1999, p. 6.
(3) OJ L 280, 13.11.1993, p. 33.
(4) OJ L 269, 11.11.1995, p. 29.
(5) OJ L 148, 6.6.1997, p. 27.
(6) See page 19 of this Official Journal.2000D0112 — EN — 08.03.2001 — 002.001 — 2
Article 2
1. Article 3 of Decision 93/590/EC is repealed.
2. Article 5 of Decision 97/348/EC is repealed.
Article 3
This Decision shall apply from "M11 July 2000 3.
Article 4
This Decision is addressed to the Member States.!B2000D0112 — EN — 08.03.2001 — 002.001 — 3
ANNEX
EUROPEAN ANTIGEN BANKDesignated antigen banks
EUROPEAN
ANTIGEN BANKIZP
BresciaLNPB
LyonMerial SAS
Pirbright/Lyon
Antigen type/subtypeQuantity (1)
(× 1 000 000)Quantity (1)
(× 1 000 000)Quantity (1)
(× 1 000 000)Totals
(× 1 000 000)
O1 — Manisa 2,5 2,5 5,0
O1 — BFS 2,5 1,0 3,5
A24 — Cruzeiro 2,5 2,5 5,0
A22 — Iraq 2,5 2,2 4,7A Iran 96 1,0 1,0
A Iran 99 1,0 1,0
A Malaysia 97 0,5 0,5C1 — Noville 2,5 2,5 5,0ASIA1 — Shamir 2,5 1,0 3,5SAT 1 0,5 0,5
SAT 2 (E Africa) 0,5 0,5SAT 2 (S Africa) 0,5 0,5
SAT 3 0,5 0,5
Quantity (
1) (× 1 000 000) total
per site10,0 9,7 11,5 31,2
(1)quantity in vaccine equivalent antigen doses.!M22000D0112 — EN — 08.03.2001 — 002.001 — 4